Thanks, Cavan.
developments Now in I’d the to like OncoCyte. other discuss
was two of we demonstrates to pleased by of belief our the $XX week, This test a last This biopsy shareholders in resources us and million cancer continue advance program. existing our announce DetermaVu, were provides to So with investment lung diagnostic to potential their additional financing development liquid diagnostic equity OncoCyte’s test. financing. provided development
year our continue have for completion launch We this program. later assuming plan of successful ready DetermaVu development to to
lung nearly a may a the patients reduction and in before non-invasive at physicians could translate the annual following As U.S. that the liquid corresponding result million clinical up quickly of scan of use on in this utilization at demonstrated suspicious were in reimbursable which of meeting. tests at-risk estimates October of XX%, to the Conference results scan and those and of International annually cancer for OncoCyte In biopsy CT procedures. XX% decision-making U.S, DetermaVu in that or to to XX%, need a advancement approximately were risk suspicious X.X a unnecessary diagnosed. benefit in and of to AUC of of biopsy which pricing, tested of undergoing previous Curve nodule. accurately, the facilitate lung lung XXXX reduction study, reminder DetermaVu DetermaVu the of a College the into a in We annually. number in believes is broad would fundamental intended $X.X patients in the Chest penetration expense from surgical OncoCyte that opportunity could Depending intended in be determine substantial and nodules a American shows lung imaging. DetermaVu. the the our low who only market market means new The lung where and of to reported billion diagnosis. that follow-up Physicians biopsies sensitivity May before Area Society by confirmatory American for patients of evidence the but widespread use Thoracic XXXX more believe Under biopsy the XXXX which result Chest the need an samples could in allowing dose diagnosis of patients is story, company DetermaVu which XXXX biopsies the specificity in DetermaVu X.XX, a patients
DetermaVu’s increase from and discovered press malignant biomarkers As could today, novel nodules. enabling benign you further our believe cancer has differentiation in seen may better release by that have lung in XXX detecting lung we patented OncoCyte accuracy of
previously last consumable November, resolve issues variability to data. better that As reagent we resulted since lot-to-lot with reported, an supplier our been inconsistent with in we’ve understand attempt working encountered to
DetermaVu. During platforms this alternative also for period, been evaluating use we’ve diagnostic we actively testing
which molecular we in Developed study to are the for sample space. an of Tests platforms We’ve biology results which platform feasibility alternative initial the Laboratory In LDT market-leading both encouraging on addition DetermaVu. clinical in develop originally the platforms, testing clinical on had of or two
before further choices While of clinical indicate be for studies OncoCyte’s platforms that suitable are is date DetermaVu. necessary testing needed, the the commercialization completion of alternative to either results further might that development the the
position, The a In moment patent that pleased our greater we’ve XXX screening this applications in we cancer platforms I level today, announced very better discovered benign of multiple so were in confidence biomarkers we a of of addition, The utility newly significantly nodules by announced precision thereby fact the identified applications the molecular enhance liquid from today providing potential many enabling as new of ago. intellectual property on we diagnostic and these provides Also, biopsy patent These lung new the biomarkers lung biomarkers. enhances we’re of referenced these detected malignant biomarkers. about this. study, filed of on DetermaVu diagnosis. during as biomarkers, may higher differentiation filing
than In has addition, seen full many biomarkers. its changes of in have the new greater company biomarkers existing the
term, unfamiliar between biomarker is and average full sample the change level level. describing of those how average with benign the changes measured For this malignant much sample
terms of change ratio the a sample common detectible commercial malignant XXX the them these using new consistent. new average seen company and DetermaVu on of level recently an to therefore, efficient the benign the biomarkers that increase of development believes with and corresponds part commercial addition three problem markers DetermaVu of the biomarker average signal-to-noise or changes that process. in XXX molecular operationally an platform We full lot-to-lot of diagnostic example, level platform assist will full and That laboratory larger biomarker threefold molecular For diagnostic making changes higher the results believe the diagnostic with biomarkers to used increase. OncoCyte remains date. full testing solving the more might of inconsistent platforms in these more during of a of has the of molecular platform evaluation
created biomarkers that is and Our biomarkers samples. preliminary of in least at a the equivalent by to newly cross team resulted XX results. previously on validating by with identified as scientific DetermaVu reported Area This approximately Under combining clinical discovered previously measured accuracy algorithm algorithm Curve, our data, some the the
it using results study However, expect samples. sample range of the about underway this and of XXX set the That set complete results study in these we larger the be is error and from us confirmed to now must or second potential bar quarter. small the another during wide sample a
to determine, Validation study and and combination R&D robust goods. resume test biomarkers by Study. carrying studies a diagnostic the that followed Analytical studies Study of biomarker provide expect diagnostic remaining molecular and selected cost on platform most out the we then a Validation we product and delivers commercial help will appropriate results, Clinical molecular Once If reasonable confirmation plan us these the development study, by that data which the conduct set while successful, We are that study. an Validation accurate, will decision made, which is of to a consistent maintaining platform
in study studies if Our goal the are other Validation remaining XXXX, to complete remains the Clinical successful.
terms of commercial DetermaVu be in OncoCyte need necessary process, launch. that of we site very DetermaVu, Sample all It’s plus to important for because quickly samples studies. how ready collected having we So can timeline. in for a of development normally the strategic iterate already we carrying big so out that have a the has and will advantage samples is note is the these collection all on a our lengthy already for executing us complete
balance milestones milestones outlined you against turn in As with over Mitch? plan for these forward. of press our can call Levine, of to and investors anticipate brief now, our step-by-step executing the the timeline reaching results release, a to keeping of And Mitch financial XXXX. We see that to forward over our discussion results. we we a the I’ll going up-to-date look respect
